How Peptides Work

Receptor Binding

Most peptides work by binding to specific receptors on the surface of target cells. This lock-and-key interaction triggers a cascade of intracellular events. Specificity is key — a well-designed peptide binds its target receptor with high affinity and minimal off-target activity, which is one reason peptides are appealing compared to small-molecule drugs.

G Protein-Coupled Receptors (GPCRs)

Many peptide hormones and research peptides act on GPCRs, the largest family of cell-surface receptors in the human body. When a peptide binds a GPCR, it activates intracellular G proteins, which modulate enzymes like adenylyl cyclase and phospholipase C, altering the concentration of second messengers such as cAMP and calcium ions.

Agonists vs Antagonists

A peptide that activates a receptor upon binding is called an agonist. One that blocks the receptor without activating it is an antagonist. Some synthetic peptides are partial agonists, producing a submaximal response — a property that can be therapeutically useful for fine-tuning biological systems.

Cellular Signaling

Receptor binding is just the first step. The downstream signaling cascades that follow determine the actual cellular response — whether that means synthesizing a protein, triggering cell growth, modulating inflammation, or altering gene expression.

Second Messenger Systems

Second messengers like cyclic AMP (cAMP), diacylglycerol (DAG), and inositol trisphosphate (IP3) relay and amplify the signal from the receptor into the interior of the cell. A single receptor activation event can trigger thousands of downstream molecular events through these amplification cascades.

Gene Expression Changes

Some peptide signaling pathways ultimately reach the cell nucleus, altering which genes are transcribed. This is how growth hormone-releasing peptides can stimulate the production of IGF-1 in the liver — the peptide signal travels from the pituitary gland through the bloodstream and eventually changes gene expression in hepatic tissue.

Bioavailability

Bioavailability refers to the fraction of an administered dose that reaches the systemic circulation in an active form. This is one of the primary practical challenges with peptide therapeutics.

Why Oral Bioavailability Is Low

Peptides are composed of amino acids connected by peptide bonds. Digestive enzymes (proteases and peptidases) in the stomach and small intestine are specifically designed to cleave these bonds, breaking peptides down into individual amino acids long before they can reach the bloodstream intact. Most research peptides are therefore administered via subcutaneous injection to bypass the gut.

Half-Life Considerations

Even after injection, peptides are subject to enzymatic degradation in the blood. Native peptides often have very short half-lives — sometimes minutes. Synthetic modifications such as PEGylation, cyclization, or the addition of fatty acid chains can extend half-life significantly, which is why compounds like CJC-1295 (with DAC) behave differently from shorter-acting analogues.

Routes of Administration

The route through which a peptide enters the body significantly affects its pharmacokinetics — how it is absorbed, distributed, metabolized, and excreted.

Subcutaneous Injection

Injection into the subcutaneous fat layer beneath the skin is the most common route for research peptides. It provides consistent absorption rates, avoids first-pass hepatic metabolism, and allows for relatively slow, sustained release into the bloodstream compared to intravenous administration.

Intranasal Administration

A small number of peptides — notably PT-141 (Bremelanotide) and oxytocin — can cross the nasal mucosa with acceptable efficiency. Intranasal delivery bypasses the blood-brain barrier challenge by accessing the olfactory pathway, which is why some neuropeptides are studied via this route.

Emerging Oral Formulations

Pharmaceutical research is actively exploring lipid nanoparticles, protease-resistant analogues, and other formulation strategies to improve oral peptide bioavailability. Semaglutide (Rybelsus) represents a notable success: an orally bioavailable GLP-1 receptor agonist achieved through co-formulation with a novel absorption enhancer.